Fidelity Management & Research Company led the round. Medical Microinstruments said in a news release that it marks the largest-ever investment in microsurgery innovation.
The company plans to use the funds to support the commercialization of its Symani surgical system in high-growth markets. Other uses include the continued investment in studies that generate clinical evidence and enable indication expansion. The company also expects to use funds to accelerate advanced technology capabilities to enable the scaling of global operational capabilities.
Pisa, Italy-based Medical Microinstruments’ Symani received CE mark in 2019, and the company continues to work on U.S. commercialization. It also has eyes on the Asia Pacific region. The first-of-its-kind robotic technology enables …